FDA Expands Cyramza Label to Include Metastatic NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA expanded the approved use of Cyramza (ramucirumab) to treat patients with metastatic non-small cell lung cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Login